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Myocardial dysfunction and coronary macro/microvascular alterations are the hallmarks of
diabetic cardiomyopathy and are ascribed to increased oxidative stress and altered nitric
oxide synthase (NOS) activity.We hypothesize that pre-treatment by cobalt-protoporphyrin
IX (CoPP) ameliorates both myocardial function and coronary circulation in streptozotocin
(STZ)-induced diabetic rats. Isolated hearts from diabetic rats in Langendorff conﬁguration
displayed lower left ventricular function and higher coronary resistance (CR) compared to
hearts from control animals. CoPP treatment of diabetic animals (0.3mg/100g body weight
i.p., once a week for 3weeks) signiﬁcantly increased all the contractile/relaxation indexes
(p <0.01),whiledecreasingCR(p <0.01).CoPPenhancedHO-1proteinlevelsandreduced
oxidative stress in diabetic animals, as indicated by the signiﬁcant (p <0.05) decrease in
heart % GSSG, O−
2 , and malondialdehyde (MDA) levels. CoPP increased adiponectin levels
and phosphorylation of AKT and AMPK and reversed the eNOS/iNOS expression imbal-
ance observed in the untreated diabetic heart. Furthermore, after CoPP treatment, a rise
in malonyl-CoA as well as a decrease in acetyl-CoA was observed in diabetic hearts. In this
experimental model of diabetic cardiomyopathy, CoPP treatment improved both cardiac
function and coronary ﬂow by blunting oxidative stress, restoring eNOS/iNOS expres-
sion balance and increasing HO-1 levels, thereby favoring improvement in both endothelial
function and insulin sensitivity.
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INTRODUCTION
According to World Health Organization, diabetes mellitus is a
global pandemic. It is associated with an increasing incidence of
heart failure, coronary artery disease, and cardiovascular mortal-
ity(LeWinter,1996;Adeghate,2004).Themechanismsresponsible
for the effects of hyperglycemia and diabetes on myocardial func-
tionandoncoronarymacro-andmicro-vasculaturearetheobject
of intensive investigation. Among several putative mechanisms,
theroleof thereactiveoxygen(ROS)andreactivenitrogenspecies
(RNS) has been studied in a number of experimental models of
diabetes (Stevens,2005). Oxidative stress associated with deﬁcient
antioxidant systems has been reported to play a critical role in
subcellular remodeling, calcium handling, and subsequent dia-
betic cardiomyopathy (Haidara et al., 2006). Nitric oxide (NO)
signaling is also involved in the genesis of diabetic myocardial and
vasculardamageandanalteredexpressionof nitricoxidesynthase
(NOS) isoforms occurs in diabetes as well as in the hyperglycemic
state (Ceriello et al., 2002; Nagareddy et al., 2005).
The levels of adiponectin, an adipocytokine secreted from the
adipose tissue (Chandran et al., 2003), are reduced in diabetes
(Hotta et al., 2000), insulin resistance (Weyer et al., 2001), and
obesity (Yamauchi et al., 2001). Decreased levels of adiponectin
have been proposed to mediate some of the deleterious effects
of diabetes on myocardial function at rest as well as in response
to ischemia (L’Abbate et al., 2007). Accordingly, administration
of adiponectin to adiponectin-deﬁcient knockout mice improved
recovery of cardiac function after myocardial ischemia (Tao et al.,
2007). Adiponectin has different cardiac effects including the
increase in myocardial insulin sensitivity, stimulation of glu-
cose uptake and lipid oxidation, increase in eNOS activity (Tao
et al., 2007), and anti-inﬂammatory action (Antoniades et al.,
2009).
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In severe diabetes, myocardial function may be depressed as
a result of multiple pathogenic mechanisms (Boudina and Abel,
2007). Impairment of myocardial function is seen in strepto-
zotocin (STZ) treated rats, a model of severe diabetes which
reproduces the clinical features of diabetic cardiomyopathy (An
and Rodrigues, 2006). However, in this model the interaction
between microvascular abnormalities and myocardial function
has never been explored. In a previous study performed in
mildly diabetic rats obtained by STZ-nicotinamide treatment,
we observed a signiﬁcant increase in microvascular resistance
during ischemia/reperfusion, associated with myocardial iNOS
overexpression, eNOS downregulation, and increased oxidative
stress (L’Abbate et al., 2007). In these diabetic rats, the cobalt-
protoporphyrin IX pre-treatment (CoPP) improved the coronary
vascular response to ischemia-reperfusion, restoring the balance
of cardiac eNOS and iNOS isoforms and the redox state. It is
also documented that CoPP treatment increases EC-SOD as well
as mitochondrial function in animal models of diabetes (Turk-
seven et al., 2005; Di Noia et al., 2006). Recently, Kusmic et al.
demonstrated that CoPP enhances the crosstalk between pAKT-
pAMPK, thus increasing NO production and bioavailability in a
mouse model of diabetes. This effect of CoPP resulted in both
local and systemic effects eventually leading to the restoration of
microvascularfunctionintheheartofdiabeticmice(Kusmicetal.,
2010).
The present study was designed to determine,in a rat model of
severe diabetes and cardiomyopathy, whether in vivo CoPP treat-
ment could improve myocardial as well as coronary function. We
examined the interaction between cardiac physiological parame-
tersandoxidativestress,focusinginparticularoneNOSandiNOS
expression and adiponectin signaling modulation.
MATERIALS AND METHODS
All experiments were approved by the Institutional Animal Care
and Use Committee of Johns Hopkins University and conducted
under the guidelines for the Care and Use of Laboratory Animals
published by the Ofﬁce of Science and Health Reports, NIH.
INDUCTION OF DIABETES
Male Wistar rats, 2months of age, received an injection of
50mg/kg streptozotocin (STZ, Sigma, St. Louis, MO, USA), i.p.,
dissolved in citrate buffer (pH 4.5), to obtain a stable diabetes
with severely reduced beta-cell mass. STZ-treated animals were
matched by a group of controls of the same age receiving the
vehicle of STZ.
ADMINISTRATION OF CoPP
CoPP was purchased from Frontier Scientiﬁc, Inc. (Logan, UT,
USA).Fourweeksafterinductionof diabetes,CoPP(0.3mg/100g
body weight), or the corresponding volume of vehicle (0.1M
sodium citrate buffer, pH 7.8) was administered subcutaneously
once a week for 3weeks. Glucose levels of diabetic rats were
checked before starting of CoPP treatment, so that animals could
be homogenously and randomly distributed between the two
groups receiving or not CoPP. In total, three groups of animals
were studied: control rats (C, n =20), diabetic rats (D, n =16),
and diabetic rats treated with CoPP (D+CoPP, n =16). At the
end of the experimental period, before excision of the heart,
blood samples were taken for glucose, insulin, and adiponectin
measurements.
ISOLATED HEART PREPARATION
ThreedaysafterthelastCoPPorvehicleinjections,ratswereanes-
thetized with i.p. pentobarbital (250units/kg) and heparinized
via the left femoral vein. The heart was rapidly excised, placed
in cold perfusion medium and weighed. The isolated heart was
attached to the Langendorff apparatus and retrogradely perfused
(at 37˚C) using constant perfusion pressure of 80cm H2O. The
perfusionmediumconsistedofoxygenatedKrebs-Henseleitbuffer
(L’Abbate et al., 2007). After 20min of stabilization, cardiac and
coronaryfunctionsweremonitored.Formeasurementof leftven-
tricularsystolic(LVP)anddiastolic(EDP)pressure,alatexballoon
was inserted into the left ventricle through the mitral valve and
connected to a Harvard pressure transducer. In each experiment,
balloon volume, and thus left ventricular volume, was adjusted
according to an EDP value of 10mmHg and maintained con-
stant for the entire duration of the experiment. For a constant
left ventricular volume and in absence of any ejection (isometric
contraction), changes in systolic pressure and dP/dtmax are pos-
itively correlated to myocardial contractility (inotropism), while
changes in dP/dtmin are positively correlated to ventricular relax-
ation. Coronary perfusion pressure (CPP) was monitored by a
second pressure transducer connected to the aortic cannula. Data
were acquired using a BIOPAC 100 System and analyzed with
AcqKnowledge software (BIOPAC system). Left ventricular devel-
opedpressure(LVDevP=LVP −EDP),heartrate(HR),dP/dtmax,
dP/dtmin, and CPP were all derived or calculated from the con-
tinuous monitoring of the LV pressure signal while LVP×HR
deﬁned the rate-pressure product (RPP), an index of cardiac
oxygen consumption and energy production.
In all the experiments, coronary ﬂow (ml/min) was contin-
uously monitored by collecting the cardiac efﬂuent. Coronary
resistance (CR) was deﬁned as CPP divided by coronary ﬂow/g
of myocardial tissue (mmHgming/ml).
BLOOD MEASUREMENTS OF GLUCOSE, INSULIN, AND ADIPONECTIN
Tail vein blood samples were collected from animals fasting for at
least 6h. Glucose levels were measured with a commercial Glu-
cose Monitor Kit (Ascensia Contour Monitoring System, Bayer)
and plasma insulin content with Rat Insulin Enzyme Immunoas-
say kit (Cayman). Plasma adiponectin was determined using an
ELISA assay (Pierce Biotechnology,Woburn, MA, USA).
TISSUE PREPARATION AND MEASUREMENT OF MALONDIALDEHYDE
(MDA), REDUCED AND OXIDIZED GLUTATHIONE, MALONYL-CoA, AND
ACETYL-CoA
Each left ventricular tissue sample was processed according to an
organicdeproteinizationproceduresuitableforthedetermination
of water-soluble low-molecular weight compounds representative
of both tissue oxido-reductive and energy status. Malondialde-
hyde (MDA), reduced and oxidized glutathione (GSH and GSSG
respectively) malonyl-CoA, and acetyl-CoA were measured by
ion-pairing HPLC (Lazzarino et al., 2003). Data acquisition and
analysis were performed using the ChromQuest software package
(Thermo Electron Corporation,Waltham,MA,USA).
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WESTERN BLOT ANALYSIS OF CARDIAC SIGNALING MOLECULES AND
HO ACTIVITY LEVEL
Frozen hearts were pulverized under liquid nitrogen and placed
in a homogenization buffer (10mM phosphate buffer, 250mM
sucrose, 1mM EDTA, 0.1mM PMSF, and 0.1% tergitol, pH
7.5) and used for measuring signaling molecules as previously
described (L’Abbate et al., 2007). Protein levels were visualized
by immunoblotting with antibodies against HO-1, HO-2 (Stress-
gen Biotechnologies Corp., Victoria, BC, Canada). Antibodies
againstAkt,pAkt,AMPK,pAMPK,andadiponectinwereobtained
from Cell Signaling Technology, Inc. (Beverly, MA, USA). eNOS,
iNOS, and p-eNOS from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Brieﬂy, 20mg of heart tissue lysate supernatant was
separated by 12% SDS/polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane. Chemiluminescence
detection was performed with the Amersham ECL detection kit
(Amersham, Piscataway, NJ, USA), according to the manufac-
turer’s instructions. The image was analyzed by densitometry.
Proteinbandswerequantiﬁedandvalueswerenormalizedtothose
of actin. One out of three separate experiments with consistent
results is shown.
HO-1 activity was assess using a scanning double beam spec-
trophotometer (Lambda 17 UV/Vis; Perkin Elmer Cetus Instru-
ments, Norfolk, CT, USA) and expressed as nmol bilirubin/mg
protein/h (L’Abbate et al., 2007).
SUPEROXIDE CARDIAC TISSUE LEVELS
Superoxide(O−
2 )wasdeterminedplacingheartsinplasticscintilla-
tion minivials,containing 5μM lucigenin for the detection of O−
2
as previously described (L’Abbate et al., 2007). Brieﬂy, cardiac tis-
sues were placed in plastic scintillation minivials containing 5μM
lucigenin in 1ml of Krebs solution buffered with 10mM HEPES-
NaOH (pH 7.4). The chemiluminescence from superoxide was
measured by a liquid scintillation counter (LS6000IC; Beckman
Instruments,San Diego,CA,USA) with a single active photomul-
tipliertubeinadarkroom.Backgroundchemiluminescenceinthe
absence of tissue was subtracted from subsequent measurements
made in the presence of BPA. The tissue was weighed at the end of
the experiment,and the counts were divided by weight to give the
readings in counts/min/mg of tissue (L’Abbate et al., 2007).
STATISTICAL ANALYSIS
Resultsarepresentedasmean±standarderrorofthemean(SEM)
of the number (n) of replicate determinations. Statistical sig-
niﬁcance between experimental groups and between different
study conditions was determined by using a two-way ANOVA,
followed by the Fisher’s exact test to evaluate two-by-two differ-
ences.Comparisonof thethreegroupswasdeterminedﬁrstdoing
an ANOVA followed by a post hoc test. p <0.05 was considered
signiﬁcant.
RESULTS
CoPP TREATMENT IMPROVES INSULIN SENSITIVITY AND INCREASES
PLASMA ADIPONECTIN LEVELS
At the end of the experimental period, plasma glucose lev-
els in diabetic (D) rats were 463.4±19.1mg/dl compared to
119±2.6mg/dl in control (C) group (p <0.01) and the corre-
sponding plasma insulin levels were 0.87±0.22ng/ml compared
to 1.9±0.35ng/ml (p <0.01) respectively. CoPP treatment low-
ered glucose levels in diabetic rats to 386.7±18mg/dl (p <0.05
vs. D) without changes in insulin levels (0.86±0.35ng/ml),
thus increasing insulin sensitivity. Plasma adiponectin levels
were signiﬁcantly lower in diabetic rats compared to controls
(3.06±1.08 vs. 8.05±0.9μg/ml; p <0.05). The administration
of CoPP to diabetic rats resulted in a marked increase in plasma
adiponectin concentration (11±1.9μg/ml,p <0.01 vs. D).
CoPP TREATMENT IMPROVES CARDIAC AND MICROVASCULAR
FUNCTION
After 20min of stabilization, hearts isolated from diabetic ani-
mals exhibited increased CR and depressed cardiac function as
compared with hearts isolated from control animals (Figure 1;
Table 1). CoPP treatment increased RPP in diabetic hearts
(p <0.005). The improvement of RPP in diabetic hearts was
the result of a combined effect of CoPP on the inotropic and
chronotropic features of the heart. Indeed, systolic LVP, LVDevP,
and dP/dtmax (all related to inotropism) were increased in
D+CoPP compared to D (p <0.005). Likewise, heart rate was
higher in D+CoPP hearts as compared to D (Table 1). More-
over,CoPP improved cardiac relaxation in D hearts (p <0.005) at
values similar to that found in control animals. When coronary
microcirculation was examined, it was found that CR was higher
in D as compared to C hearts (p <0.01) and returned back to
control values after CoPP pre-treatment (Figure 1).
EFFECT OF CoPP TREATMENT ON HO-1 AND HO-2 EXPRESSION AND HO
ACTIVITY
DiabeticheartsdisplayedlowerHO-1proteinlevelsandlowerHO
activity (p <0.05 vs. C) compared to those found in control ani-
mals (Figures 2A,B). CoPP treatment caused an increase in both
HO-1 protein levels and HO activity in diabetic animals (p <0.01
vs. D; Figure 2). Both the diabetic condition and pre-treatment
with CoPP did not inﬂuence the levels of HO-2 protein (upper
left panel).
EFFECT OF CoPP TREATMENT ON GLUTATHIONE, MDA, O
−
2 AND 3-NT
When compared to control,heart tissue in D rats showed a higher
valueof %GSSG[GSSG/GSH+GSSG)×100],mostlikelydepen-
dent on a shift of redox balance towards an oxidative state. This
value went back to a value close to that of controls after CoPP
administration (p <0.01; Figure 3). Moreover, a similar trend in
the GSH balance was also found by considering the GSH/GSSG
r a t i o( Cr a t s=16.98; D rats=8.17; CoPP rats=11.21). In addi-
tion to altered glutathione balance, diabetic hearts exhibited a
ﬁve-fold increase in O−
2 levels compared to controls (p <0.05 vs.
C), that was completely reversed upon CoPP treatment (p <0.01
D+CoPP vs. D; Figure3). Compared to controls,diabetic hearts
showedremarkablyhigherlevelsof MDA,anindexof lipidperox-
idation (p <0.01 vs. C). In D+CoPP rats, both MDA and 3-NT
levels found returned toward normal values of control animals,
probably as a consequence of HO-1 induction (Figure 3).
CoPP TREATMENT INCREASES CARDIAC LEVELS OF eNOS, p-eNOS,
AND iNOS
Consistent with previous observations, we found a lower value of
p-eNOS/eNOS ratio in hearts isolated from diabetic animals than
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FIGURE 1 |After 30min of stabilization, dP/dtmax, and dP/dtmin,
rate-pressure product (RPP), and levels of coronary resistance (CR) in
control rats (C, n =20), diabetic rats (D, n =15), and diabetic rats treated
for 3weeks with CoPP (D+CoPP , both n =16). Data are expressed as
means±SEM. *p <0.05 vs. other groups;
#p <0.05 vs. CoPP-treated
animals.
Table 1 | Hemodynamic parameters in control rats (C, n =20), diabetic
rats (D, n =16), and diabetic rats treated for 3weeks with CoPP
(D+CoPP , n =16).
HR (beats/min) LVP (mmHg) LVDP (mmHg)
C( n=20) 213±31 2 0 ±61 1 0 ±4
D( n=16) 178 ±3* 93±9# 81±5#
D+CoPP (n=16) 207±41 0 5 ±5* 94±3*
Data are expressed as means±SEM. HR, heart rate; LVP , left ventricular sys-
tolic pressure; LVDP , left ventricular developed pressure calculated as described
in Section “Materials and Methods,” *p<0.05 vs. other groups,
#p<0.05 vs.
controls.
fromcontrols(p <0.05;Figure4).CoPPtreatmentincreasingthe
levels of p-eNOS augmented the p-eNOS/eNOS ratio (p <0.05
D vs. D+CoPP and C; Figure 4). Hearts from diabetic animals
showed an increased expression of iNOS, that was signiﬁcantly
attenuated upon CoPP treatment (Figure 4).
CoPP TREATMENT INCREASES CARDIAC LEVELS OF AKT, AMPK, AND
ADIPONECTIN
In the hearts from diabetic animals, a signiﬁcant (p <0.005)
decreaseofpAKTandpAMPKlevelswasobserved,ascomparedto
controls, without any change in Akt and AMPK (Figure 5). CoPP
fully reversed these changes,normalizing pAKT,and even increas-
ing pAMPK levels in diabetic hearts. As shown in Figure 5 (lower
panel), adiponectin levels were signiﬁcantly decreased in diabetic
cardiac tissue, but were restored by CoPP treatment (p <0.05 D
vs. D+CoPP).
CoPP TREATMENT INCREASES CARDIAC LEVELS OF MALONYL-CoA
AND DECREASES LEVELS OF ACETYL-CoA
Diabetes resulted in a signiﬁcant decrease in the myocardial lev-
els of malonyl-CoA (p <0.01) associated to a signiﬁcant increase
(p <0.05) of acetyl-CoA (Figure 6). Both these changes were
normalized after CoPP treatment.
DISCUSSION
In the present study we demonstrate that CoPP administration
increased expression of HO-1 and reversed both myocardial and
coronary dysfunction in the STZ rat model of diabetes. In this
model of severe diabetes, myocardial function is reduced and CR
is increased (Koch et al., 2003; Boudina and Abel, 2007), thus
mimicking the clinical nature of diabetic cardiomyopathy with
increased coronary microvascular resistance. We demonstrate for
the ﬁrst time in this report a complete reversal of LV systolic and
diastolic dysfunction by treatment with the HO-1 protein inducer
CoPP.
Following CoPP treatment, the normalization of myocardial
function and the reduction of CR in diabetic hearts were asso-
ciated with a decrease in oxidative stress and improved cardiac
markers of endothelial function. In particular, CoPP treatment
resulted in the reversion of overexpression of iNOS found in
the diabetic heart and the restoration of eNOS expression. This
contrasting effect of CoPP on cardiac eNOS and iNOS, lead-
ing to the normalization of the expression balance of the two
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FIGURE 2 | HO-1/HO-2 expression and HO activity in C, D, and
D+CoPP rat hearts. Heart samples were subjected to Western
blotting for the determination of HO-1/HO-2 protein.
A representative blot is shown. Densitometric analysis of HO-1 vs.
actin is shown and expressed as means±SEM of three
independent experiments. HO activity was determined by bilirubin
formation (see Materials and Methods). *p <0.05 vs. other
groups.
FIGURE 3 | Cardiac tissue levels of (A) % GSSG
[GSSG/(GSH+GSSG)×100], (B) O
−
2, and (C) malonyldialdehyde (MDA)
measured in hearts from C, D, and D+CoPP rats. (D) Representative
Western blot and densitometric analysis of 3-nitrotyrosine (3-NT) expression in
cardiac tissue of C, D, and D+CoPP rats. Data are expressed as means±SEM
of three independent determinations *p <0.05 vs. other groups.
isoforms, could have synergistically contributed to the improve-
ment of both myocardial and vascular functions of the diabetic
heart.
It is well known that the beneﬁcial effects of CoPP are medi-
ated by HO-1 induction (Di Noia et al., 2006; Li et al., 2008). In
particular, the effect on NOS balance can be ascribed to HO-1,
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since Turkeseven et al. demonstrated that the effect of CoPP was
associated with an increase in EC-SOD and NO bioavailability. In
contrast,adecreaseinHO-1andinhibitionofHOactivityresulted
in an increase in superoxide levels in healthy animals (Turkseven
et al.,2005).
Theimprovementof coronaryandmyocardialfunctionindia-
betic animals described here mirror the systemic humoral effects
of CoPP that were manifest by the activation of the HO-1/
adiponectin pathway. Previously, we showed the active role of
HO-1 in the stimulation of adiponectin secretion. In fact, the
inhibition of HO activity by administration of tin mesopor-
phyrin (SnMP) after CoPP treatment resulted in decreased levels
of plasmaadiponectin(L’Abbateetal.,2007).Accordingly,Lietal.
(2008) showed that the co-administration of CoPP and SnMP
resulted in the loss of the beneﬁcial effects associated with the
increased expression of HO-1. The effects of CoPP on increas-
ing the levels of adiponectin were associated with the systemic
enhancement of insulin sensitivity,cardiac modulation of glucose
uptake, and fatty acid oxidation resulting in improvement in
myocardial function.
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Reactiveoxygenspecieshavebeenidentiﬁedasaprimarycause
for both the development and progression of diabetic cardiomy-
opathy(BoudinaandAbel,2007).Indeed,inthepresentstudy,the
beneﬁcial effects of CoPP on CR and myocardial function in dia-
betes were associated with a marked reduction of oxidative stress
markersincardiactissue.CoPPtreatmentreducedthecardiaclev-
els of superoxide, oxidized glutathione, and MDA. This beneﬁcial
effectonredoxbalanceislikelydrivenbybilirubin,producedfrom
degradationofhemebyHO-1,whichhasstrongantioxidantprop-
ertiesaswellascytoprotectiveeffectsonthecardiovascularsystem
(Abraham and Kappas, 2008).
The diabetic heart exhibits a progressive decrease in eNOS
expression which is accompanied by a concomitant rise in iNOS
expression (Bardell and MacLeod, 2001; Boudina and Abel, 2007;
L’Abbateetal.,2007).Wealsofounddownregulationof eNOSand
overexpression of iNOS in the diabetic rat heart, both reversible
upon CoPP treatment. Inducible NOS produces a higher amount
of NO than other isoforms. In conditions of oxidative stress,such
as in the diabetic heart, the overproduction of NO results in NO
interacting with superoxide and contributing to the formation
of RNS including peroxynitrite. Besides reducing NO availability,
peroxynitrite is a strong oxidant and can oxidize various bio-
molecules and exert cytotoxic actions in both myocardial and
vascular tissue resulting in cardiovascular derangement. Perox-
ynitrite formation is associated with several pathophysiological
conditions including acute myocardial infarction and chronic
ischemicheartfailure(Weinsteinetal.,2000;Pacheretal.,2003).It
contributestothepathogenesisof diabeticcardiovascularcompli-
cations while its pharmacological decomposition improves both
diastolic and systolic function in diabetic heart (Szabo et al.,
2002). Peroxynitrite depresses cardiac function through differ-
ent mechanisms including cellular necrosis or α-actinin nitration
and its effective neutralization can have a signiﬁcant therapeutic
beneﬁt.
In addition to decreased iNOS levels and NO production,
thus blunting the formation and deleterious effects of abnor-
mal amounts of peroxynitrite, increased levels of p-eNOS were
observedfollowingCoPPtreatment.ThismaybeduetotheCoPP-
mediated increases in plasma and cardiac tissue adiponectin.
Adiponectin differentially regulates NO production from eNOS
andiNOS:throughcrosstalkbetweenAMPKandAKT,itpromotes
eNOS phosphorylation pathways, increasing eNOS activity (Tao
et al., 2007). Recently, it was reported that ventricular cardiomy-
ocytes also express adiponectin receptors leading to increased
glucoseuptakeandfattyacidoxidationinnormalrats(Dingetal.,
2007) thus improving their metabolic proﬁle (Kim et al., 2007).
Human studies demonstrate that plasma adiponectin regulates
insulinreceptorphosphorylationcontributingtoincreasedinsulin
sensitivity (Yamauchi et al., 2001; Stefan et al., 2004). In brief,
adiponectin has both metabolic and vascular actions stimulating
the endothelial production of NO and reduction in its levels may
contribute to insulin resistance and endothelial/myocardial dys-
function (Dimmeler et al., 1999). Our results are also in keeping
with the report that adiponectin is critical for endothelial cell sur-
vival and function (Ouchi et al., 2004) via the activation of eNOS
and pAKT and pAMPK signaling.
In the normal heart, both fatty acid oxidation and glucose
metabolism contribute to energy production. Conversely,the dia-
betic heart relies almost completely on fatty acids, as glucose
uptake and subsequent utilization is impaired (Lopaschuk,1996).
There are several explanations for this switch in substrate uti-
lization in diabetic heart. First,insulin-dependent glucose uptake,
via the glucose transporter (GLUT) 4, is decreased, thus glucose
metabolism (both glycolysis and glucose oxidation) is depressed.
Second, the release of FFA from adipose tissue is increased.
Despite an increase in FFA utilization in diabetic heart, it is
likely that FFA uptake exceeds oxidation rate resulting in lipid
accumulation in the myocytes and lipotoxicity (Sharma et al.,
2004).Furthermore,lipidintermediatesmightpromoteapoptosis
of cardiomyocytes, thus representing an additional mechanism
leading to cardiac dysfunction. In order to explore the effect
of adiponectin and HO-1 elevation on diabetic cardiac metab-
olism, we measured cardiac malonyl-CoA, a key mediator in
the β-oxidation, due to its inhibitory effect on carnitine palmi-
toyltransferase 1. With normal insulin sensitivity, malonyl-CoA
increases when the muscle feeds on glucose (plasma insulin levels
increased),while it decreases when the muscle is glucose deprived
(plasma insulin levels decreased; Ruderman et al., 1999; Park
et al., 2002). Insulin exerts its lipogenic effect increasing cellular
malonyl-CoA via dephosphorylation and activation of acetyl-
CoA carboxylase, thus supporting fatty acid synthesis instead of
degradation.Hence,adecreaseininsulinavailabilityreducesintra-
cellular malonyl-CoA levels and fatty acid oxidation increases.
The present study conﬁrms that the decreased insulin secretion
(due to STZ injection) reduces malonyl-CoA formation. Follow-
ing CoPP administration, HO-1 induction reverses the decrease
of malonyl-CoA observed in diabetic heart. The normalization
of malonyl-CoA suggests a favorable effect on diabetic car-
diac metabolism toward glucose utilization and prevention of
cellular lipotoxicity (Figure 7). Since insulin sensitizing prop-
erties have been ascribed, to adiponectin, we speculate that
malonyl-CoA-dependent decrease in β-oxidation might be due to
adiponectin release or HO-1 induction. Anyway, further studies
using adiponectin or HO-1 knockout mice are needed to explain
the degree of involvement of these molecules in the control of
β-oxidation rate in the heart.
Recently, it was reported that the effect of adiponectin on glu-
cose uptake is mediated by p38MAPK-increasing GLUT4 translo-
cation. However,adiponectin can also stimulate the translocation
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FIGURE 7 | Diagrammatic representation of the major changes observed in diabetic heart after CoPP treatment as compared to untreated hearts.
Black arrows represent results demonstrated in this paper and, blue arrows represent previously shown work and/or hypothesis drawn from the literature.
of GLUT4 via PI-3-kinase, the same signaling cascade activated
by insulin (Figure 7). Human studies demonstrate that plasma
adiponectin and HO-1 expression regulate insulin sensitivity and
insulin receptor phosphorylation (Yamauchi et al., 2001; Stefan
et al., 2004) contributing to increased insulin sensitivity. As a
consequence, enhanced glucose utilization in CoPP-treated dia-
betic hearts could contribute toward a glucose-dependent energy
repletion which in turn has the potential to enhance cellular
malonyl-CoA. Together with improved myocardial perfusion and
increased malonyl-CoA, reduced β-oxidation of FFA in myocar-
dial cells could attenuate lipid peroxidation, oxidative stress, and
improve myocytes function.
Taken together, the results of the present study promote the
use of compounds that increase HO-1 expression, HO activ-
ity, and adiponectin levels as a therapeutic means of both
preventing and reversing the cardiomyopathy associated with
diabetes.
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